However, one alectinib-resistant cancer did not feature resistance to ALK, yet, a PIK3CA G106V mutation was found, known to be linked to EGFR inhibitor treatment resistance in EGFR-mutant NSCLC [48]. This evidence concerns the gene ALK and cancer.